<DOC>
	<DOCNO>NCT00628303</DOCNO>
	<brief_summary>The primary objective study assess efficacy motavizumab compare placebo administer monthly preterm infant first RSV season reduction incidence serious early childhood wheeze 2nd 3rd birthday .</brief_summary>
	<brief_title>A Phase 3 Trial Effect Motavizumab Prophylaxis Reduction Serious Early Childhood Wheezing Infants</brief_title>
	<detailed_description>The primary objective study assess efficacy motavizumab compare placebo administer monthly intramuscular ( IM ) injection first RSV season reduction incidence serious early childhood wheeze preterm infant 2nd 3rd birthday .</detailed_description>
	<mesh_term>Respiratory Sounds</mesh_term>
	<criteria>Male female infant bear 32 &amp; 1/7 35 &amp; 0/7 week GA , determine accord available medical record Chronological age &lt; 6 month age randomization In good health , opinion investigator Not one follow AAPdefined risk factor : 1 . Childcare attendance 2 . Schoolaged sibling 3 . Exposure environmental air pollutant ( include passive exposure tobacco smoke ) Ability willingness subject 's parent/legal guardian complete protocolmandated followup telephone contact , visit procedure Written inform consent obtain subject 's parent ( ) legal guardian Diagnosis CLD prematurity ( also refer BPD ) chronic pulmonary disease Diagnosis hemodynamically significant CHD , define require medication supplemental oxygen CHD Congenital abnormality airways Severe neuromuscular disease , determine investigator Previous concurrent treatment palivizumab intravenous immunoglobulin ( IVIG ) Eligible prophylaxis base local medical standard guideline participate site Known immunodeficiency Previous current diagnosis upper low respiratory infection medical professional Previous current diagnosis wheezing , asthma , wheezingrelated diagnosis Hospitalization time enrollment ( case admit nursery part routine care , infant randomize immediately prior discharge ) Any illness condition would preclude longterm survival Participation trial investigational agent RSV prophylaxis therapy Inability follow 3rd birthday</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Months</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Good health</keyword>
</DOC>